Semaglutide in Singapore – Ozempic & Wegovy Guide for Diabetes & Weight Loss
What is Semaglutide?
Semaglutide is a prescription medication used to manage type 2 diabetes and obesity. In Singapore, it is available as:
- Ozempic: Weekly injection for diabetes
- Wegovy: Weekly injection for weight loss
Semaglutide works by mimicking GLP-1, a hormone that regulates blood sugar and appetite, helping patients manage glucose levels and reduce body weight.
How Semaglutide Works
Semaglutide acts on GLP-1 receptors throughout the body to:
- Increase insulin secretion after meals
- Reduce glucagon release from the liver
- Slow stomach emptying for longer satiety
- Suppress appetite via brain signaling
These mechanisms make semaglutide effective for blood sugar control and weight management.
Benefits of Semaglutide
For Diabetes
(Ozempic)
- Lowers HbA1c by 1–2%
- Reduces post-meal glucose spikes
- Supports long-term blood sugar control
For Obesity
(Wegovy)
- Achieves 5–15% body weight reduction
- Improves metabolic health and obesity-related conditions
For Heart
Health
- 26% reduction in cardiovascular events (heart attack, stroke, death)
- Lowers blood pressure and cholesterol
Key Clinical Trials
- Investigated Ozempic injections for type 2 diabetes
- Showed significant HbA1c reduction vs standard therapy
- Weight loss: 4.5–6.5 kg over 30–56 weeks
- Adults with BMI >30 or BMI >27 with comorbidities
- Wegovy 2.4mg weekly vs placebo over 68 weeks
- Results
- Adults with BMI >30 or BMI >27 with comorbidities
- 50%+ lost over 15% of body weight
- Most side effects were temporary gastrointestinal issues
Results of the 68 week STEP 1 trial
- High-risk diabetes patients on Ozempic
- 26% reduction in major cardiovascular events
- Fewer heart attacks, strokes, and cardiovascular deaths
Emerging Benefits
- Fertility: Improved hormonal balance linked to weight loss
- Alcohol & Smoking Reduction: Small trials show reduced cravings
- Fatty Liver Disease (NAFLD/MAFLD): Ongoing studies suggest metabolic and weight loss benefits
SURPASS-2 Trial: Tirzepatide (Mounjaro) versus Semaglutide (Ozempic) for diabetes
Safety and Side Effects
Semaglutide is generally well tolerated:
Common:
- Nausea, vomiting, diarrhea, constipation
- Headaches, dizziness
- Weight-loss related facial changes (“Ozempic face”)
Rare but serious:
- Gallstones, pancreatitis
- Overdose
Switching Between Formulations
Patients may switch between Ozempic and Wegovy- both contain the same active ingredient
Ozempic Wegovy and Semaglutide injections are trending
Where to buy Semaglutide (Ozempic & Wegovy) in Singapore
- Prescription-only; must consult a doctor in a licenced medical clinic
- Avoid unverified online sources due to risk of counterfeit drugs
Price of Semaglutide (Ozempic & Wegovy) in Singapore
- $500-800 per month depending on dosage
Dosage Guidelines
Ozempic & Wegovy: Start with low dose (0.25–0.5mg/week), increase gradually:
- Medium dose: Ozempic 1mg/week
- Maximum dose: Ozempic 2mg/week, Wegovy 2.4mg/week
Gradual dose escalation helps reduce gastrointestinal side effects and improve tolerance.
Conclusion
Once weekly Semaglutide injections (Ozempic are Wegovy) is a proven, safe, and effective treatment for diabetes, obesity, and cardiovascular risk. These medications are prescription only so patients should follow their doctor’s guidance.
Semaglutide and diabetes: SUSTAIN 1-7 clinical trials
At a glance summary of SUSTAIN trials: Diabetic and overweight patients controlled their diabetes and lost weight when treated with Ozempic, even more so as compared to standard diabetic medication.
In the SUSTAIN 1-7 series of clinical trials which investigated the effectiveness of once weekly semaglutide injections (Ozempic) for the treatment of diabetic and obese patients, semaglutide (Ozempic) consistently demonstrated significant reductions in HbA1c levels compared to placebo and other usual diabetes medications (metformin, sitagliptin, dulaglutide). In addition, diabetic patients treated over a 30-56 week period experienced 4.5-6.5kg weight loss.
Semaglutide and obesity: STEP1 clinical trial
Summary of STEP 1 trial: Patients treated with high dose once weekly semaglutide 2.4mg injections (WeGovy) lost a significant amount of weight over a 68 week period.
The STEP 1 clinical trial, published in the New England Journal of Medicine in 2021, involved 1961 adult patients with obesity (BMI >30) or overweight (BMI >27 with 1 obesity related comorbidity). The patients were randomised into treatment arm with once weekly semaglutide 2.4mg (WeGovy) versus placebo. After 68 weeks, the patient group treated with once weekly semaglutide 2.4mg (WeGovy) experienced significant weight loss of 14.9% body weight reduction versus 2.4% placebo group. The average amount of weight loss in the treatment group was 15.3kg, as compared to 2.6kg in the placebo group. Most of the patients treated with WeGovy lost a significant amount of weight: 32% of patients lost over 20% body weight, 50.5% of patients lost over 15% body weight loss, 69.1% achieved 10% body weight loss and 86.4% achieved 5% body weight loss. Nausea and diarrhea were the most common side effects which were transient and improved with time, with less than 5% of the patients in the treatment group discontinuing treatment from gastrointestinal side effects.
Semaglutide and Cardiovascular risk: SUSTAIN 6 trial
Summary: The SUSTAIN 6 trial looked at the cardiovascular outcomes (cardiovascular death, heart attack and stroke) in high cardiovascular risk diabetic patients being treated with semaglutide (Ozempic) versus placebo- with the results showing a significant 26% reduction in cardiovascular death, heart attack and stroke in patients being treated with semaglutide (Ozempic).
The SUSTAIN 6 trial showed that in patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke was significantly lower among patients receiving semaglutide (Ozempic) than among those receiving placebo. 3297 patients with type 2 diabetes were treated with once-weekly semaglutide injections (0.5 mg or 1.0 mg Ozempic) or placebo for 104 weeks. The primary outcome was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. At baseline, 2735 of the patients (83.0%) had established cardiovascular disease, chronic kidney disease, or both. The primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide treatment group and in 146 of 1649 patients (8.9%) in the placebo group- representing a 26% reduction in risk.
Frequently Asked Questions
What is semaglutide and how is it different from Ozempic and Wegovy?
Semaglutide is the active ingredient found in both Ozempic and Wegovy. Ozempic is approved for type 2 diabetes management, while Wegovy uses a higher dose of semaglutide specifically for medical weight loss.
How does semaglutide (Ozempic and Wegovy) help with weight loss?
Semaglutide works by activating GLP-1 receptors, which reduces appetite, slows digestion, and helps you feel full longer. These effects naturally lower calorie intake and support fat loss.
Is Wegovy available in Singapore?
Wegovy is available in Singapore (~July 2025 onwards)
How long does it take for Ozempic or Wegovy to show results?
Most people notice changes in appetite within the first 2 weeks, while significant weight or blood sugar improvements typically appear between 8–12 weeks of consistent use.
What is the recommended starting dose for semaglutide (Ozempic and Wegovy)?
Doctors usually begin with the lowest dose (0.25-0.5 mg weekly for injections) to minimise side effects, then increase the dose of Ozempic or Wegovy gradually.
What are the most common side effects of semaglutide (Ozempic and Wegovy)?
Common reactions include nausea, constipation, diarrhea, and bloating. These symptoms are usually mild and improve as your body adapts to the medication.
Is semaglutide (Ozempic and Wegovy) safe for long-term use?
Clinical studies show that long-term use is generally safe when monitored by a healthcare professional. Regular follow-ups are important to track glucose, weight, and potential side effects.
Can I use semaglutide if I am not diabetic?
Yes, people without diabetes may use semaglutide for medically supervised weight loss—specifically the Wegovy formulation or off-label Ozempic depending on availability.
What foods or drinks should I avoid while taking semaglutide?
There are no strict food restrictions, but patients often feel better avoiding heavy or oily meals which may lead to bloating
Can I stop semaglutide (Ozempic and Wegovy) once I reach my goal weight?
Stopping the medication may lead to weight regain because appetite and metabolic changes return to baseline. Many patients transition to a maintenance plan guided by their doctor and may require low dose treatment long term
Can semaglutide be combined with other weight loss medications?
Combination therapy should only be done under a doctor’s supervision. Some medications may increase side effects or overlap in how they suppress appetite.
What happens if I miss a dose of Ozempic or Wegovy?
If it has been less than 5 days since your missed dose, take it as soon as you remember. If more than 5 days have passed, skip it and resume your normal weekly schedule. Do not double-dose.
Does semaglutide cause low blood sugar?
Semaglutide itself usually does not trigger hypoglycemia. However, the risk increases if it’s taken with insulin or sulfonylureas, so dose adjustments may be needed.
Can I take semaglutide while trying to conceive or during pregnancy?
Current guidelines recommend stopping semaglutide at least 2 months before conception. It should not be used during pregnancy or breastfeeding.
Is there a difference between the weight loss from Ozempic and Wegovy?
Yes. Wegovy contains a higher approved dose (up to 2.4 mg weekly) which generally results in greater weight loss compared to the maximum Ozempic dose of 2 mg.
Are the results permanent after stopping semaglutide?
Most users regain some of the lost weight if they discontinue treatment without a maintenance plan. Long-term lifestyle changes are important for lasting results.
Does semaglutide help reduce cravings for food, alcohol, or smoking?
Many patients report fewer cravings, especially for high-calorie foods. Early research suggests semaglutide may also reduce alcohol and nicotine urges, but more studies are needed.
What’s the difference between Ozempic injections and Rybelsus tablets?
Both contain semaglutide. Ozempic is a once-weekly injection, while Rybelsus is a daily oral tablet. They differ in absorption rate and dosing convenience.
How should I store Ozempic or Wegovy pens?
Unopened pens must be kept refrigerated. Once opened, they can be stored at room temperature for up to 30 days but should not be exposed to heat or direct sunlight.
Who should avoid taking semaglutide?
Semaglutide may not be suitable for individuals with a history of gallstones, pancreatitis, medullary thyroid carcinoma and MEN2 syndrome. Pregnant or breastfeeding females are also not suitable.
Contact Us
Book An Appointment Now
Take the first step toward a healthier, more confident you. Our medical team is ready to answer your questions and guide you through safe, personalised weight-loss options. Reach out today to schedule a consultation or speak with our care specialists.